Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:17:57.372Z.
Calculation as of: 2026-10-06T21:17:57.372Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.05M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.46M
Price/FCF Ratio
27.57
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$14.73M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.20M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.94M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.05M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | 27.57 | 28.16 | 28.16 | 28.16 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
